drugset

drugset / Trial / NCT00619229

Alprostadil in Maculopathy Study (AIMS)

NCT00619229 ↗

Phase 3 Terminated 37 enrolled UCB Pharma

RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluation of efficacy of alprostadil (prostaglandin E1) for treatment of patients suffering from dry age-related macula degeneration

Timeline

Start: 2006-07
Primary completion: 2010-02
Completion: 2010-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alprostadil	Unknown	60 ug	Intravenous

Indications